These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6232970)

  • 1. Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
    Sakata Y; Mimuro J; Aoki N
    Blood; 1984 Jun; 63(6):1393-401. PubMed ID: 6232970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
    Sakata Y; Aoki N
    J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin.
    Sakharov DV; Lijnen HR; Rijken DC
    J Biol Chem; 1996 Nov; 271(44):27912-8. PubMed ID: 8910391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Jackson KW; McKee PA
    Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
    Rouy D; Anglés-Cano E
    Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.
    Angles-Cano E; Rouy D; Lijnen HR
    Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation.
    Henderson SJ; Stafford AR; Leslie BA; Kim PY; Vaezzadeh N; Ni R; Fredenburgh JC; Weitz JI
    Thromb Haemost; 2015 Jun; 113(6):1278-88. PubMed ID: 25789495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots.
    Tran-Thang C; Kruithof EK; Bachmann F
    J Clin Invest; 1984 Dec; 74(6):2009-16. PubMed ID: 6210307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis.
    Ho-Tin-Noé B; Rojas G; Vranckx R; Lijnen HR; Anglés-Cano E
    FEBS J; 2005 Jul; 272(13):3387-400. PubMed ID: 15978044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
    Suenson E; Thorsen S
    Biochem J; 1981 Sep; 197(3):619-28. PubMed ID: 6459779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
    Sakata Y; Eguchi Y; Mimuro J; Matsuda M; Sumi Y
    Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin-associated plasminogen activation in alpha 2-plasmin inhibitor deficiency.
    Aoki N; Sakata Y; Ichinose A
    Blood; 1983 Nov; 62(5):1118-22. PubMed ID: 6626743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors that control extravascular fibrinolysis.
    Chung SI; Lee SY; Uchino R; Carmassi F
    Semin Thromb Hemost; 1996; 22(6):479-88. PubMed ID: 9122712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis.
    Suenson E; Lützen O; Thorsen S
    Eur J Biochem; 1984 May; 140(3):513-22. PubMed ID: 6233145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.